Power 3 Medical Products Inc. (OTCBB: PWRM)

Power3 Medical Products Inc. (PWRM) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. The Company’s products also comprise NuroPro, a blood serum protein neurodegenerative disease diagnostic screening test for disease diagnostics, such as neurological diseases of motor control, such as Parkinson’s disease, ALS, and similarly disorders; ALS specific tests for ALS vs. ALS-like disorders; Alzheimer’s disease specific tests; and a Parkinson’s disease specific test.

PWRM has a joint-venture agreement with NeoGenomics. In the area of neurodegenerative diseases and breast cancer, PWRM has completed research and clinical validation studies involving more than 1,500 patient samples. PWRM uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company has discovered protein biomarker patterns in more than 1,500 patient samples that cover a range of diseases.

The Company was founded in 1992 and is based in The Woodlands, Texas.

Source: Reuters.com, SEC Filings.

Financial Summary

Source: Reuters.com, SEC Filings.

Analyst Consensus

No chart available.

Source: www.ft.com

No consensus analysis data available.

Source: http://www.reuters.com/finance/stocks/estimates?symbol=PWRM.OB

Investment Highlights

In early September PWRM announced the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal Biochemical and Biophysical Research Communications.

The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson’s disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples. The analytic technology forms the basis for the NuroPro®PD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with PWRM signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

PWRM announced in late August that it has made significant advances in the technology for its BC-SeraPro serum protein-based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications. As disclosed in the patent applications, PWRM has identified a group of 22 blood serum proteins with abnormal concentrations in women with breast cancer.

Using the Company’s BC-SeraPro platform, PWRM used these protein biomarkers to distinguish women with breast cancer from those with benign abnormal breast conditions and with normal breasts with sensitivities and specificities in the 80%-90% range, in retrospective banked and prospective newly drawn samples from patients and controls. The biomarkers also distinguish between women with purely invasive primary breast cancer and women who also have ductal carcinoma in situ, which is often missed in mammograms. In addition, following the “Principals of Omic Medicine” that Dr. Goldknopf is promoting at international scientific meetings in the US and China, the company has disclosed methods for making biomarker specific antibodies for development of a user friendly commercial test for breast cancer.

Source: http://www.power3medical.com/investor/investorrelations.aspx?level=1

Technical Analysis

Source: http://stockcharts.com

PWRM is trading above its 50 day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

PWRM is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

The MACD for PWRM currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9day moving average. Second, the MACD is above 0 which implies that the underlying moving averages are trending higher.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.